Cargando…

International Variability of Renal and Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus in Europe

INTRODUCTION: Type 2 diabetes and its complications represent a huge burden to public health. With this prospective, observational cohort study, we aimed to estimate and to compare the incidence rate (IR) of renal and cardiovascular outcomes and all-cause mortality in patients with type 2 diabetes i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thöni, Stefanie, Keller, Felix, Denicolò, Sara, Eder, Susanne, Buchwinkler, Lukas, Rosivall, Laszlo, Wiecek, Andrzej, Mark, Patrick B., Rossing, Peter, Heerspink, Hiddo L., Mayer, Gert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077442/ https://www.ncbi.nlm.nih.gov/pubmed/37015210 http://dx.doi.org/10.1159/000528438

Ejemplares similares

Biological variation and reference change value of the estimated glomerular filtration rate in humans: A systematic review and meta-analysis
por: Thöni, Stefanie, et al.
Publicado: (2022)

Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers
por: Kerschbaum, Julia, et al.
Publicado: (2020)

Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study
por: Denicolò, Sara, et al.
Publicado: (2022)

Population Characteristics and Clinical Outcomes from the Renal Transplant Outcome Prediction Validation Study (TOPVAS)
por: Sallaberger, Sebastian, et al.
Publicado: (2022)

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus
por: Pena, Michelle J., et al.
Publicado: (2016)

Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment
por: Lohia, Sonnal, et al.
Publicado: (2023)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes
por: Møller, Alexandra Louise, et al.
Publicado: (2023)

Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation
por: Buchwinkler, Lukas, et al.
Publicado: (2021)

Humoral Immune Response to a Timely Booster mRNA Vaccination in Non-Responders to a Standard Vaccination Schedule against COVID-19 in Kidney Transplant Recipients
por: Stigler, Julia, et al.
Publicado: (2022)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
por: Rossing, Peter, et al.
Publicado: (2023)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Response
por: Vogi, Verena, et al.
Publicado: (2022)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study)
por: de Boer, Stefanie A., et al.
Publicado: (2020)

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Waijer, Simke W., et al.
Publicado: (2020)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

In silico deconjugation of glucuronide conjugates enhances tandem mass spectra library annotation of human samples
por: Huber, Carolin, et al.
Publicado: (2022)

Assessment of Fibrinogen-like 2 (FGL2) in Human Chronic Kidney Disease through Transcriptomics Data Analysis
por: Denicolò, Sara, et al.
Publicado: (2022)

Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years
por: Lawson, Claire A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k4j555ron4nus3s7d5dvivi4io